scholarly journals Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)

BMC Neurology ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
D. Delgado ◽  
L. Canham ◽  
N. Cotterill ◽  
D. Cottrell ◽  
M. J. Drake ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

BMC Neurology ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Marcus J. Drake ◽  
Luke Canham ◽  
Nikki Cotterill ◽  
Debbie Delgado ◽  
Jenny Homewood ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
Double Blind ◽  
Double Blind Placebo

Double-Blind, Placebo-Controlled, Randomized, Crossover Trial of High-Dose Methylprednisolone in Patients with Chronic Progressive Form of Multiple Sclerosis

1995 ◽  
Vol 35 (4) ◽  
pp. 193-198 ◽  
Author(s):  
Giuseppe Cazzato ◽  
Tiziana Mesiano ◽  
Rodolfo Antonello ◽  
Fabrizio Monti ◽  
Nicola Carraro ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
High Dose ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Randomized Crossover Trial ◽  
High Dose Methylprednisolone ◽  
Progressive Form

American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study

2011 ◽  
Vol 17 (12) ◽  
pp. 1523-1526 ◽  
Author(s):  
E Kim ◽  
M Cameron ◽  
J Lovera ◽  
L Schaben ◽  
D Bourdette ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
American Ginseng ◽  
Single Center ◽  
Severity Scale ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Fatigue Severity ◽  
Improve Fatigue

This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial

Neurology ◽  
1996 ◽  
Vol 47 (6) ◽  
pp. 1457-1462 ◽  
Author(s):  
C. T. Bever ◽  
P. A. Anderson ◽  
J. Leslie ◽  
H. S. Panitch ◽  
S. Dhib-Jalbut ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Leg Strength ◽  
Multiple Sclerosis Patients

scholarly journals Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

BMJ ◽  
2004 ◽  
Vol 329 (7460) ◽  
pp. 253 ◽  
Author(s):  
Kristina B Svendsen ◽  
Troels S Jensen ◽  
Flemming W Bach
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
Central Pain ◽  
Double Blind ◽  
Double Blind Placebo

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine

2001 ◽  
Vol 7 (6) ◽  
pp. 354-358 ◽  
Author(s):  
P.M. Rossini ◽  
P. Pasqualetti ◽  
C. Pozzilli ◽  
M.G. Grasso ◽  
E. Millefiorini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Crossover Trial ◽  
Progressive Multiple Sclerosis ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial

2021 ◽  
pp. 100895
Author(s):  
Jens Christian Laursen ◽  
Niels Søndergaard-Heinrich ◽  
Joana Mendes Lopes de Melo ◽  
Bryan Haddock ◽  
Ida Kirstine Bull Rasmussen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Crossover Trial ◽  
Acute Effects ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document